Samsung Bioepis SB27 meets Phase 3 endpoint as Keytruda biosimilar competition accelerates
Read how Samsung Bioepis SB27’s positive Phase 1 and Phase 3 data could reshape the Keytruda biosimilar race and oncology access.
Why CytoDyn Inc.’s leronlimab data could reshape TNBC immunotherapy strategies
Discover how CytoDyn Inc.’s leronlimab data could reshape TNBC immunotherapy and expand checkpoint treatment potential.
Is Kazia’s paxalisib becoming the new backbone for checkpoint combos?
Kazia Therapeutics Limited has presented new clinical and translational data at the 2025 San Antonio Breast Cancer Symposium demonstrating that paxalisib, its investigational brain-penetrant PI3K/mTOR inhibitor, may suppress circulating tumor cell clusters and reverse immune exhaustion in two of the most treatment-resistant breast cancer subtypes—HER2-positive metastatic breast cancer and triple-negative breast cancer. The early evidence, […]